OraSure In-Home HIV Test’s Promise Outweighs Risks, Panel Concludes
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Blood Products Advisory Committee endorses OraSure’s OraQuick in-home HIV test in a unanimous 17-0 vote on May 15. If approved, OraQuick would be the first-ever over-the-counter test for HIV that can be performed entirely in the home by untrained users.
You may also be interested in...
OraSure Over-The-Counter HIV Test: Complete PMA Filing Planned By Year End
OraSure Technologies expects to complete a PMA filing for its OraQuick Advance rapid HIV-1 and -2 over-the-counter saliva test by the end of the year.
CDRH Focusing On New PMA Pathway, Clinical Trials Program In 2014/2015 Priorities
CDRH Director Jeffrey Shuren discussed the device center’s two-year strategic priorities with “The Gray Sheet.” The center plans to rebalance pre-market and post-market data collection, when appropriate, and improve the processes for starting up clinical trials in the U.S.
FDA Emphasizes “Deregulatory” Efforts In Mobile Medical Apps Final Guidance
In a long-awaited final guidance, FDA affirmed its plan to practice enforcement discretion for most mobile medical apps, except those applications that present the same risks as conventional FDA-regulated devices. Some digital health stakeholders praised the guidance, while others wished FDA had waited.